Acurx Pharmaceuticals, Inc. (ACXP) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -186.15%, forward earnings yield 37.45%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -10.0 | 0.00 | 72.20 | 0.00 | - |
| 2020 | -17.0 | 0.75 | 28.96 | 0.00 | - |
| 2021 | -3.5 | -0.02 | 3.56 | 0.00 | - |
| 2022 | -3.6 | 0.34 | 5.88 | 0.00 | - |
| 2023 | -3.3 | -1.15 | 10.40 | 0.00 | - |
| 2024 | -1.0 | 0.04 | 22.54 | 0.00 | - |
| 2025 | -0.5 | 0.01 | 0.71 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.60 | $0.00 | $-5.93M | - |
| 2020 | $-0.46 | $0.00 | $-4.6M | - |
| 2021 | $-1.24 | $0.00 | $-12.75M | - |
| 2022 | $-1.12 | $0.00 | $-12.09M | - |
| 2023 | $-1.15 | $0.00 | $-14.58M | - |
| 2024 | $-872.54 | $0.00 | $-14.1B | - |
| 2025 | $-5.32 | $0.00 | $-7.97M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.16 | $-2.16 – $-2.16 | $276K | $276K – $276K | 1 |
| 2027 | $-2.09 | $-2.09 – $-2.09 | $3.54M | $3.54M – $3.54M | 1 |
| 2028 | $-2.08 | $-2.08 – $-2.08 | $25.31M | $25.31M – $25.31M | 1 |
| 2029 | $-1.82 | $-1.82 – $-1.82 | $47.49M | $47.49M – $47.49M | 1 |
| 2030 | $1.16 | $1.16 – $1.16 | $62.67M | $62.67M – $62.67M | 1 |
